Literature DB >> 5681169

Pituitary growth hormone suppression with low-dosage, long-acting corticoid administration.

R S Stempfel, B M Sheikholislam, H E Lebovitz, E Allen, R C Franks.   

Abstract

Mesh：

Substances：

Year:  1968        PMID： 5681169     DOI： 10.1016/s0022-3476(68)80188-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  7 in total

1.  Identical male twins with congenital adrenal hyperplasia. Comparison of growth, serum and urinary steroids.

Authors:  M H Connors; B M Sheikholislam
Journal:  West J Med       Date:  1976-04

2.  Growth and skeletal maturation in congenital adrenal hyperplasia. Review of 20 cases.

Authors:  C C Bailey; G M Komrower
Journal:  Arch Dis Child       Date:  1974-01       Impact factor: 3.791

3.  Corticosteroid therapy and growth.

Authors: 
Journal:  Br Med J       Date:  1969-02-15

4.  Management of congenital adrenal hyperplasia. Urinary steroid estimations--review of their value.

Authors:  C C Bailey; G M Komrower; M Palmer
Journal:  Arch Dis Child       Date:  1978-02       Impact factor: 3.791

5.  Glucocorticosteroids and growth hormone secretion under physiological conditions and in states of steroid excess.

Authors:  K E Mühlendahl; B Weber; R Müller-Hess; S Korth-Schütz; H Helge
Journal:  Eur J Pediatr       Date:  1978-06-20       Impact factor: 3.183

6.  Growth and body proportions in congenital adrenal hyperplasia.

Authors:  M C Young; J Ribeiro; I A Hughes
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

7.  Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3.

Authors:  P Sarzi-Puttini; F Atzeni; J Schölmerich; M Cutolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.